Ueber Pellote. Ein Beitrag zur pharmakologischen Kenntniss der Cacteen. In: Archiv für experimentelle Pathologie und Pharmakologie. Band 34, 1894, S. 65–86 (Digitalisat, doi:10.1007/bf01864855); Ueber Pellote. Beiträge zur chemischen und pharmakologischen Kenntniss der Cacteen. Zweite Mittheilung. In: Archiv für experimentelle Pathologie und Pharmakologie. Band 40, 1898, S. 385–429 (Digitalisatdoi:10.1007/BF01825267).
T. Passie, U. Benzenhöfer: MDA, MDMA, and other “mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s). In: Drug testing and analysis. Band 10, Nummer 1, Januar 2018, S.72–80, doi:10.1002/dta.2292, PMID 28851034 (Review).
L. Lewin: Ueber Anhalonium Lewinii. In: Archiv für Experimentelle Pathologie und Pharmakologie. Band 24, 1888, S.401–411, doi:10.1007/bf01923627.
Ueber Pellote. Ein Beitrag zur pharmakologischen Kenntniss der Cacteen. In: Archiv für experimentelle Pathologie und Pharmakologie. Band 34, 1894, S. 65–86 (Digitalisat, doi:10.1007/bf01864855); Ueber Pellote. Beiträge zur chemischen und pharmakologischen Kenntniss der Cacteen. Zweite Mittheilung. In: Archiv für experimentelle Pathologie und Pharmakologie. Band 40, 1898, S. 385–429 (Digitalisatdoi:10.1007/BF01825267).
Ernst Späth: Über die Anhalonium-Alkaloide: I. Anhalin und Mezcalin. In: Monatsh. Chem. 40, Nr.2, 1919, S.129–154; doi:10.1007/BF01524590.
O. Ogunbodede, D. McCombs, K. Trout, P. Daley, M. Terry: New mescaline concentrations from 14 taxa/cultivars of Echinopsis spp. (Cactaceae) (“San Pedro”) and their relevance to shamanic practice. In: Journal of ethnopharmacology. Band 131, Nummer 2, September 2010, S.356–362, doi:10.1016/j.jep.2010.07.021, PMID 20637277.
Yohei Hashimoto, Kazuko Kawanishi, Masataka Moriyasu: Forensic Chemistry of Alkaloids by Chromatographic Analysis. In: The Alkaloids: Chemistry and Pharmacology. Band 32, 1988, S. 40 (doi:10.1016/S0099-9598(08)60215-1).
Bonnie Glass-Coffin:Shamanism and San Pedro through Time: Some Notes on the Archaeology, History, and Continued Use of an Entheogen in Northern Peru. In: Anthropology of Consciousness. Band21, Nr.1, März 2010, S.58–82, doi:10.1111/j.1556-3537.2010.01021.x.
Hesham R. El-Seedi, Peter A. G. M. De Smet, Olof Beck, Göran Possnert, Jan G. Bruhn:Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. In: Journal of Ethnopharmacology. Band101, Nr.1, 3.Oktober 2005, S.238–242, doi:10.1016/j.jep.2005.04.022.
A. Rickli, O. D. Moning, M. C. Hoener, M. E. Liechti: Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. In: European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. Band 26, Nummer 8, August 2016, S.1327–1337; doi:10.1016/j.euroneuro.2016.05.001, PMID 27216487.
K. D. Charalampous, K. E. Walker, John Kinross-Wright: Metabolic fate of mescaline in man. In: Psychopharmacologia. Bd. 9, 1966, S.48–63; doi:10.1007/BF00427703.
Teri S. Krebs, Pål-Ørjan Johansen, Lin Lu: Psychedelics and Mental Health: A Population Study. In: PLoS ONE. Bd. 8, 2013, S.e63972, doi:10.1371/journal.pone.0063972.
J. P. Finberg: Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. In: Pharmacology & therapeutics. Band 143, Nummer 2, August 2014, S.133–152, doi:10.1016/j.pharmthera.2014.02.010, PMID 24607445 (Review).
D. I. Brierley, C. Davidson: Developments in harmine pharmacology: implications for ayahuasca use and drug-dependence treatment. In: Progress in neuro-psychopharmacology & biological psychiatry. Band 39, Nummer 2, Dezember 2012, S.263–272, doi:10.1016/j.pnpbp.2012.06.001, PMID 22691716 (Review).
R. S. Gable: Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. In: Addiction. Band 102, Nummer 1, Januar 2007, S.24–34, doi:10.1111/j.1360-0443.2006.01652.x, PMID 17207120 (Review).
T. Passie, U. Benzenhöfer: MDA, MDMA, and other “mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s). In: Drug testing and analysis. Band 10, Nummer 1, Januar 2018, S.72–80, doi:10.1002/dta.2292, PMID 28851034 (Review).
O. Ogunbodede, D. McCombs, K. Trout, P. Daley, M. Terry: New mescaline concentrations from 14 taxa/cultivars of Echinopsis spp. (Cactaceae) (“San Pedro”) and their relevance to shamanic practice. In: Journal of ethnopharmacology. Band 131, Nummer 2, September 2010, S.356–362, doi:10.1016/j.jep.2010.07.021, PMID 20637277.
A. T. Shulgin, M. F. Carter: Centrally active phenethylamines. In: Psychopharmacology communications. Band 1, Nummer 1, 1975, S.93–98, PMID 1223994.
C. Gambelunghe, R. Marsili, K. Aroni, M. Bacci, R. Rossi: GC-MS and GC-MS/MS in PCI mode determination of mescaline in peyote tea and in biological matrices. In: J Forensic Sci. Bd. 58, Nr. 1, Januar 2013, S. 270–278, PMID 22900815.
L. A. Nisbet, F. M. Wylie, B. K. Logan, K. S. Scott: Gas Chromatography-Mass Spectrometry Method for the Quantitative Identification of 23 New Psychoactive Substances in Blood and Urine. In: J Anal Toxicol. Bd. 43, Nr. 5, 1. Juni 2019, S. 346–352, PMID 30698723.
S. Yang, Y. Shi, Z. Chen, M. Chen, X. Liu, W. Liu, M. Su, B. Di: Detection of mescaline in human hair samples by UPLC-MS/MS: Application to 19 authentic forensic cases. In: J Chromatogr B Analyt Technol Biomed Life Sci. Bd. 1195, 15. April 2022, S. 123202, PMID 35248899.
A. Rickli, O. D. Moning, M. C. Hoener, M. E. Liechti: Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. In: European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. Band 26, Nummer 8, August 2016, S.1327–1337; doi:10.1016/j.euroneuro.2016.05.001, PMID 27216487.
J. H. Halpern, H. G. Pope: Hallucinogen persisting perception disorder: what do we know after 50 years? In: Drug and alcohol dependence. Band 69, Nummer 2, März 2003, S.109–119, PMID 12609692 (Review).
F. Sjöqvist: Psychotropic drugs (2): Interaction between monoamine oxidase (MAO) inhibitors and other substances. In: Proceedings of the Royal Society of Medicine. Band 58, Nummer 11 Part 2, November 1965, S.967–978, PMID 4952963, PMC1898666(freier Volltext) (Review).
M. G. Livingston, H. M. Livingston: Monoamine oxidase inhibitors: An update on drug interactions. In: Drug safety. Band 14, Nummer 4, April 1996, S.219–227, PMID 8713690 (Review).
J. P. Finberg: Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. In: Pharmacology & therapeutics. Band 143, Nummer 2, August 2014, S.133–152, doi:10.1016/j.pharmthera.2014.02.010, PMID 24607445 (Review).
D. I. Brierley, C. Davidson: Developments in harmine pharmacology: implications for ayahuasca use and drug-dependence treatment. In: Progress in neuro-psychopharmacology & biological psychiatry. Band 39, Nummer 2, Dezember 2012, S.263–272, doi:10.1016/j.pnpbp.2012.06.001, PMID 22691716 (Review).
R. S. Gable: Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. In: Addiction. Band 102, Nummer 1, Januar 2007, S.24–34, doi:10.1111/j.1360-0443.2006.01652.x, PMID 17207120 (Review).
Laura Larco:Archivo Arquidiocesano de Trujillo Sección Idolatrías. (Años 1768–1771). In: Más allá de los encantos: Documentos históricos y etnografía contemporánea sobre extirpación de idolatrías en Trujillo (siglos XVIII-XX) (=Travaux de l’IFEA). Institut français d’études andines, Lima 2015, ISBN 978-2-8218-4453-7, S.67–87 (openedition.org[abgerufen am 15.April 2022]).